# US 2009/0270359 A1 · Substituted pyrazole derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0270359 A1
- Document ID: US20090270359A1
- Status: Published application
- Kind: A1
- Application number: 12/199,008
- Filed: 2008-08-27
- Published: 2009-10-29
- Earliest claimed: 2007-08-30
- Assignees: Takeda Pharmaceutical Company Limited
- Inventors: Mitsuhiro ITO; Tomohiko SUZAKI; Satoshi YAMAMOTO
- Web page: https://patentgrep.com/patent/US20090270359A1

## CPC

- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A61P 5/28: Antiandrogens
- A61P 13/08: of the prostate
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07D 417/14: containing three or more hetero rings
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a novel pyrazole derivative and an androgen receptor antagonist containing the derivative. The present invention provides a compound represented by the formula (I′) wherein R1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R2 is a phenyl group having cyano (the phenyl group may further have substituent(s) other than cyano); R3 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R4 is a cyclic group optionally having substituent(s); and X is methylene optionally having substituent(s), or CO, or a salt thereof.

## Claims

### Claim 1

A compound represented by the formula (I′) or a salt thereof,
wherein
R1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom;
R2 is a phenyl group having cyano (the phenyl group optionally further has substituent(s) other than cyano);
R3 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom;
R4 is a cyclic group optionally having substituent(s); and
X is CO or methylene optionally having substituent(s).

### Claim 2 (depends on 1)

The compound of claim 1, wherein the cyclic group optionally having substituent(s) for R4 is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrazyl, 5-pyrimidyl, 5-imidazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 4-isoxazolyl, 5-isoxazolyl, 4-oxazolyl, 1,2,3-triazol-4-yl, 5-thiadiazolyl, 3-indolyl, 6-quinolyl, 5-benzotriazolyl, 2-benzothienyl, 3-benzothienyl, thienopyrazol-5-yl, 2-tetrahydrofuryl, 2-tetrahydropyranyl, piperidin-3-yl, 4-dihydrobenzofuranyl, 7-dihydrobenzofuranyl, 1,3-benzodioxol-5-yl, 1,4-benzodioxan-5-yl, 1,4-benzodioxan-6-yl, 1,5-benzodioxepin-6-yl, 1,5-benzodioxepin-7-yl, dihydroisoindol-5-yl, 1,2,3,4-tetrahydrophthalazin-6-yl, 2,3-dihydro-1,4-benzodioxin-5-yl, 2,3-dihydro-1,4-benzodioxin-6-yl, 3,4-dihydro-2H-1,5-benzodioxepin-6-yl or 3,4-dihydro-2H-1,5-benzodioxepin-7-yl.

### Claim 3

A compound represented by the formula (IA) or a salt thereof,
wherein
ring A is a benzene ring optionally further having substituent(s) other than cyano;
ring B is an aromatic hydrocarbon ring optionally having substituent(s) or heterocycle optionally having substituent(s);
R5 and R6 are the same or different and each is a hydrogen atom, a cyano group, a C1-6 alkyl group optionally having substituent(s), —COORa, —CONRaRb or —NRaCORb;
Ra and Rb are the same or different and each is a hydrogen atom, a C1-6 alkyl group optionally having substituent(s), a C3-7 cycloalkyl group or a phenyl group optionally having substituent(s); and
R7 is a hydrogen atom, a C1-6 alkyl group, a C3-7 cycloalkyl group, or a phenyl group optionally having substituent(s).

### Claim 4 (depends on 3)

The compound of claim 3, wherein ring A is a benzene ring optionally further having substituent(s) other than cyano, which is/are selected from a halogen atom, a C1-6 alkyl group, a halogeno-C1-6 alkyl group, and —ORc wherein Rc is a hydrogen atom, a C1-6 alkyl group optionally having substituent(s) or a C3-7 cycloalkyl group.

### Claim 5 (depends on 3)

The compound of claim 3, wherein ring B is a benzene ring optionally having substituent(s), a pyridine ring optionally having substituent(s), a thiazole ring optionally having substituent(s) or a pyrazole ring optionally having substituent(s).

### Claim 6 (depends on 3)

The compound of claim 3, wherein ring B is a benzene ring, a pyridine ring, a thiazole ring or a pyrazole ring, which optionally has substituent(s) selected from a halogen atom, a C1-6 alkyl group optionally having substituent(s), a C2-6 alkenyl group optionally having substituent(s), a C2-6 alkynyl group optionally having substituent(s), a nitro group, a phenyl group optionally having substituent(s), a heterocyclic group optionally having substituent(s), a cyano group, —CONRdRe, —CO2Rd, —NRdCORe, —SO2NRdRe, —NRdSO2Re, —C(OH)RdRe, —NRdRe, —ORd and —SRd wherein Rd and Re are the same or different and each is a hydrogen atom, a C1-6 alkyl group optionally having substituent(s), a C3-7 cycloalkyl group or a phenyl group optionally having substituent(s).

### Claim 7 (depends on 3)

The compound of claim 3, wherein R5 and R6 are the same or different and each is a hydrogen atom, a cyano group, a C1-6 alkyl group, a halogeno-C1-6 alkyl group, —CONRaRb or —NRaCORb.

### Claim 8

3-{[4-(3-Chloro-4-cyanophenyl)-3,5-dimethyl-1H-pyrazol-1-yl]methyl}benzamide, or a salt thereof.

### Claim 9

4-{[4-(3-Chloro-4-cyanophenyl)-3,5-dimethyl-1H-pyrazol-1-yl]methyl}benzamide or a salt thereof.

### Claim 10

5-{[4-(3-Chloro-4-cyanophenyl)-3,5-dimethyl-1H-pyrazol-1-yl]methyl}-2-fluorobenzamide or a salt thereof.

### Claim 11

5-{[4-(3-Chloro-4-cyanophenyl)-3,5-dimethyl-1H-pyrazol-1-yl]methyl}pyridine-2-carboxamide or a salt thereof.

### Claim 12

5-{[4-(3-Chloro-4-cyanophenyl)-3,5-dimethyl-1H-pyrazol-1-yl]methyl}-N-methylpyridine-2-carboxamide or a salt thereof.

### Claim 13

4-{[4-(3-Chloro-4-cyanophenyl)-3,5-dimethyl-1H-pyrazol-1-yl]methyl}-N-(2-hydroxy-2-methylpropyl)benzamide or a salt thereof.

### Claim 14

2-Chloro-4-{3,5-dimethyl-1-[4-(5-methyl-1,3,4-oxadiazol-2-yl)benzyl]-1H-pyrazol-4-yl}benzonitrile or a salt thereof.

### Claim 15

4-{[4-(3-Chloro-4-cyanophenyl)-3,5-dimethyl-1H-pyrazol-1-yl]methyl}-N-cyclopropylbenzamide or a salt thereof.

### Claim 16

5-{[4-(3-Chloro-4-cyanophenyl)-3,5-dimethyl-1H-pyrazol-1-yl]methyl}-N-cyclopropylpyridine-2-carboxamide or a salt thereof.

### Claim 17

5-({4-[4-Cyano-3-(trifluoromethyl)phenyl]-3,5-dimethyl-1H-pyrazol-1-yl}methyl)pyridine-2-carboxamide or a salt thereof.

### Claim 18

4-{[4-(3-Chloro-4-cyanophenyl)-3,5-dimethyl-1H-pyrazol-1-yl]methyl}benzenesulfonamide or a salt thereof.

### Claim 19

4-{[4-(3-Chloro-4-cyano-2-fluorophenyl)-3,5-dimethyl-1H-pyrazol-1-yl]methyl}benzamide or a salt thereof.

### Claim 20

2-Chloro-4-(3,5-dimethyl-1-{[6-(5-methyl-1,3,4-oxadiazol-2-yl)pyridin-3-yl]methyl}-1H-pyrazol-4-yl)benzonitrile or a salt thereof.

### Claim 21 (depends on 1, 3)

A prodrug of the compound of claim 1 or 3.

### Claim 22 (depends on 1, 3)

A pharmaceutical agent comprising the compound of claim 1 or 3, or a prodrug thereof.

### Claim 23 (depends on 22)

The pharmaceutical agent of claim 22, which is an androgen receptor antagonist.

### Claim 24 (depends on 22)

The pharmaceutical agent of claim 22, wherein the androgen receptor is a normal androgen receptor and/or a mutant androgen receptor.

### Claim 25 (depends on 22)

The pharmaceutical agent of claim 22, which is an agent for the prophylaxis or treatment of hormone sensitive cancer in the androgen-dependent phase and/or the androgen-independent phase.

### Claim 26 (depends on 22)

The pharmaceutical agent of claim 22, which is an agent for the prophylaxis or treatment of prostate cancer.

### Claim 27 (depends on 1, 3)

A method of antagonizing an androgen receptor, comprising administering an effective amount of the compound of claim 1 or 3, or a prodrug thereof to a mammal.

### Claim 28 (depends on 1, 3)

A method of preventing • treating a hormone sensitive cancer in the androgen-dependent phase and/or the androgen-independent phase, comprising administering an effective amount of the compound of claim 1 or 3, or a prodrug thereof to a mammal.

### Claim 29 (depends on 1, 3)

A method of preventing • treating prostate cancer, comprising administering an effective amount of the compound of claim 1 or 3, or a prodrug thereof to a mammal.

### Claim 30 (depends on 1, 3)

Use of the compound of claim 1 or 3, or a prodrug thereof for the production of an androgen receptor antagonist.

### Claim 31 (depends on 1, 3)

Use of the compound of claim 1 or 3, or a prodrug thereof for the production of an agent for the prophylaxis•treatment of a hormone sensitive cancer in the androgen-dependent phase and/or the androgen-independent phase.

### Claim 32 (depends on 1, 3)

Use of the compound of claim 1 or 3, or a prodrug thereof for the production of an agent for the prophylaxis•treatment of prostate cancer.
